-       Report 
- October 2025
-  194 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- October 2025
-  116 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- April 2025
-  175 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- May 2024
-  100 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- October 2024
-  200 Pages 
- Global 
   From       €3354EUR$3,750USD£2,950GBP 
             -       Report 
- June 2025
-  119 Pages 
- Thailand 
   From       €2280EUR$2,549USD£2,006GBP 
      €2682EUR$2,999USD£2,360GBP 
             The Cannabis Pharmaceuticals market within the context of Analgesics is a rapidly growing sector of the pharmaceutical industry. Cannabis-based pharmaceuticals are used to treat a variety of conditions, including chronic pain, inflammation, and neurological disorders. These drugs are often used in combination with traditional analgesics to provide a more comprehensive approach to pain management. Cannabis-based pharmaceuticals are also being studied for their potential to reduce opioid dependence    and addiction.
Cannabis-based pharmaceuticals are available in a variety of forms, including oral capsules, topical creams, and sublingual sprays. These products are often formulated with other active ingredients, such as cannabinoids, terpenes, and flavonoids, to provide additional therapeutic benefits.
Several companies are currently operating in the Cannabis Pharmaceuticals market, including GW Pharmaceuticals, Tilray, and Zynerba Pharmaceuticals. These companies are focused on developing and commercializing cannabis-based pharmaceuticals for the treatment of various conditions. Show Less   Read more